Atrys Health SL (ATRY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Atrys Health SL (ATRY) has a cash flow conversion efficiency ratio of -0.031x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.67 Million ≈ $-5.46 Million USD) by net assets (€151.96 Million ≈ $177.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ATRY stock market capitalisation for the company's overall valuation and market capitalisation.
Atrys Health SL - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Atrys Health SL's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Atrys Health SL Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atrys Health SL ranked by their cash flow conversion efficiency. Explore ATRY operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rxsight Inc
NASDAQ:RXST
|
-0.036x |
|
Thirumalai Chemicals Limited
NSE:TIRUMALCHM
|
-0.175x |
|
Arwana Citramulia Tbk
JK:ARNA
|
0.090x |
|
Tah Hsin Industrial Corp
TW:1315
|
0.013x |
|
Naturgy BAN SA
BA:GBAN
|
0.231x |
|
TerrAscend Corp
F:TED
|
0.081x |
|
AG Mortgage Investment Trust Inc
NYSE:MITT
|
0.037x |
|
High Tide Inc
NASDAQ:HITI
|
0.057x |
Annual Cash Flow Conversion Efficiency for Atrys Health SL (2015–2025)
The table below shows the annual cash flow conversion efficiency of Atrys Health SL from 2015 to 2025. View Atrys Health SL share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €151.96 Million ≈ $177.65 Million |
€-1.56 Million ≈ $-1.82 Million |
-0.010x | -186.69% |
| 2024-12-31 | €253.24 Million ≈ $296.07 Million |
€3.00 Million ≈ $3.50 Million |
0.012x | +413.87% |
| 2023-12-31 | €289.88 Million ≈ $338.90 Million |
€-1.09 Million ≈ $-1.28 Million |
-0.004x | +91.75% |
| 2022-12-31 | €337.57 Million ≈ $394.66 Million |
€-15.43 Million ≈ $-18.04 Million |
-0.046x | -366.86% |
| 2021-12-31 | €273.98 Million ≈ $320.31 Million |
€4.69 Million ≈ $5.49 Million |
0.017x | +192.45% |
| 2020-12-31 | €75.33 Million ≈ $88.07 Million |
€-1.40 Million ≈ $-1.63 Million |
-0.019x | -168.34% |
| 2019-12-31 | €39.95 Million ≈ $46.71 Million |
€1.08 Million ≈ $1.27 Million |
0.027x | +178.48% |
| 2018-12-31 | €26.44 Million ≈ $30.91 Million |
€-913.68K ≈ $-1.07 Million |
-0.035x | -161.14% |
| 2017-12-31 | €23.30 Million ≈ $27.24 Million |
€1.32 Million ≈ $1.54 Million |
0.057x | +201.57% |
| 2016-12-31 | €14.26 Million ≈ $16.68 Million |
€-793.63K ≈ $-927.84K |
-0.056x | -258.82% |
| 2015-12-31 | €11.70 Million ≈ $13.68 Million |
€409.89K ≈ $479.21K |
0.035x | -- |
About Atrys Health SL
Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through three segments: Diagnosis, Oncology, and Preventive Medicine. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; telediagnosis activities in the fi… Read more